Silexion Therapeutics LTD Price & Performance (SLXN)

Silexion Therapeutics has finalized an expanded development strategy for its siRNA candidate, SIL204, aimed at addressing KRAS-driven cancers. The plan, informed by promising preclinical data, will be showcased at the upcoming NeauxCancer 2025 Conference. The strategy is expected to enhance SIL204’s clinical potential through innovative delivery methods.123

Recent preclinical findings reveal SIL204's effectiveness in reducing tumor growth and metastasis in orthotopic pancreatic cancer models. These results demonstrate significant reductions in tumor burden, validating the therapy's systemic delivery approach. Silexion plans to leverage these insights to accelerate development and broaden applications for KRAS-driven cancers.423

Silexion Therapeutics has successfully retired a $1.25 million convertible note with EarlyBirdCapital. The agreement involved a combination of cash and share issuance, reducing the company’s financial obligations. This move is part of broader efforts to strengthen its financial position as it advances its pipeline of RNAi therapies.567